Reidenberg M, Drayer D
Clin Pharmacokinet. 1984; 9 Suppl 1:18-26.
PMID: 6705423
DOI: 10.2165/00003088-198400091-00003.
Robertz G, DENGLER H
Klin Wochenschr. 1983; 61(13):649-53.
PMID: 6688447
DOI: 10.1007/BF01487581.
Droge J, Janssen L, Wilting J
Pharm Weekbl Sci. 1983; 5(5):228-33.
PMID: 6646989
DOI: 10.1007/BF02332949.
Lee C, Marbury T
Clin Pharmacokinet. 1984; 9(1):42-66.
PMID: 6362952
DOI: 10.2165/00003088-198409010-00003.
Sullivan P, Murnaghan D, Callaghan N, Kantamaneni B, Curzon G
J Neurol Neurosurg Psychiatry. 1980; 43(8):739-43.
PMID: 6159456
PMC: 490648.
DOI: 10.1136/jnnp.43.8.739.
Disease-induced variations in plasma protein levels. Implications for drug dosage regimens (Part II).
Zini R, Riant P, Barre J, Tillement J
Clin Pharmacokinet. 1990; 19(3):218-29.
PMID: 2203581
DOI: 10.2165/00003088-199019030-00005.
Plasma protein binding of phenylbutazone during recovery from acute renal failure.
Mussche M, Belpaire F, Bogaert M
Eur J Clin Pharmacol. 1975; 9(1):69-71.
PMID: 1233255
DOI: 10.1007/BF00613431.
Binding of amobarbital, pentobarbital and diphenylhydantoin to blood cells and plasma proteins in healthy volunteers and uraemic patients.
Ehrnebo M, Odar-Cederlof I
Eur J Clin Pharmacol. 1975; 8(6):445-53.
PMID: 1233247
DOI: 10.1007/BF00562320.
Lack of relationship between serum free fatty acids and impaired plasma protein binding of diphenylhydantoin in chronic renal failure.
Odar-Cederlof I, Borga O
Eur J Clin Pharmacol. 1976; 10(6):403-5.
PMID: 1001355
DOI: 10.1007/BF00563076.
The bioavailability, dispostion kinetics and dosage of sulphadimethoxine in dogs.
Baggot J, Ludden T, POWERS T
Can J Comp Med. 1976; 40(3):310-7.
PMID: 1000393
PMC: 1277771.
Factors affecting drug binding in plasma of elderly patients.
Wallace S, Whiting B
Br J Clin Pharmacol. 1976; 3(2):327-30.
PMID: 973967
PMC: 1428869.
DOI: 10.1111/j.1365-2125.1976.tb00611.x.
Binding of four sulphonamides to human albumin.
Zini R, dAthis P, Hoareau A, Tillement J
Eur J Clin Pharmacol. 1976; 10(2):139-45.
PMID: 964290
DOI: 10.1007/BF00609473.
Protein binding of salicylate and quinidine in plasma from patients with renal failure, chronic liver disease and chronic respiratory insufficiency.
Perez-Mateo M, Erill S
Eur J Clin Pharmacol. 1977; 11(3):225-31.
PMID: 856605
DOI: 10.1007/BF00606415.
Distribution of pentobarbital and diphenylhydantoin between plasma and cells in blood: effect of salicylic acid, temperature and total drug concentration.
Ehrnebo M, Odar-Cederlof I
Eur J Clin Pharmacol. 1977; 11(1):37-42.
PMID: 832656
DOI: 10.1007/BF00561786.
The binding of drugs to plasma proteins from patients with poor renal function.
Reidenberg M
Clin Pharmacokinet. 1976; 1(2):121-5.
PMID: 797494
DOI: 10.2165/00003088-197601020-00003.
Binding of drugs to human muscle.
Fichtl B, Kurz H
Eur J Clin Pharmacol. 1978; 14(5):335-40.
PMID: 729627
DOI: 10.1007/BF00611903.
Investigations on salicylate protein binding in newborns and infants.
WINDORFER A, Karitzky D, Gasteiger U, Stehr K
Eur J Pediatr. 1978; 127(3):163-72.
PMID: 648538
DOI: 10.1007/BF00442057.
Plasma protein binding of phenytoin and warfarin in patients undergoing renal transplantation.
Odar-Cederlof I
Clin Pharmacokinet. 1977; 2(2):147-53.
PMID: 324689
DOI: 10.2165/00003088-197702020-00005.
[Pharmaco-kinetic aspects of protein-binding (author's transl)].
Kurz H
Klin Wochenschr. 1978; 56(24):1195-204.
PMID: 32427
DOI: 10.1007/BF01477075.
Protein binding of antimicrobials: clinical pharmacokinetic and therapeutic implications.
Craig W, Welling P
Clin Pharmacokinet. 1977; 2(4):252-68.
PMID: 20259
DOI: 10.2165/00003088-197702040-00002.
